FY2021 · ended Dec 31, 2021 · Revenue $0 · Filed Feb 24, 2023
Gri Bio, Inc. (GRI) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$10.2 million. As of Jun 30, 2026 it held $10.9 million in cash and investments and $44,000 in total debt.
Revenue (TTM)
$-100,000
Net income (TTM)
$-6.97M
Operating cash flow (TTM)
$-10.41M
-13.6% vs year-ago TTM
Free cash flow
$-10.19M
-18.3% vs prior year
EPS
$-121.80
+92.1% vs prior year
Dividend per share
None
Shares outstanding
1.45M
+175.1% vs prior year
Net cash
$10.90M
as of Jun 30, 2026
Operating margin
9291.0%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1824293
- Former names
- Vallon Pharmaceuticals, Inc. (until Apr 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$12.0M | -$8.2M | -$11.4M | -$2.2M | -$9.3M |
| Net income | -$12.0M | -$8.2M | -$13.0M | -$3.2M | -$9.3M |
| Diluted EPS | -$121.80 | -$1,545.55 | -$5,018.09 | -$24.95 | -$1.42 |
| Operating cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M | — | -$8.3M |
| Total assets | $8.7M | $5.7M | $3.0M | $383,000 | $8.3M |
| Total liabilities | $2.7M | $1.7M | $2.7M | $2.0M | $2.5M |
| Stockholders' equity | $6.0M | $4.0M | $259,000 | -$1.6M | -$4.8M |
| Cash and investments | $8.2M | $5.0M | $1.8M | $9,000 | $7.5M |
| Total debt | $71,000 | $119,000 | $14,000 | $0 | $169,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Nov 4, 2026 | Nov 4, 2026 |
| ARS | Annual report to shareholders | Sep 28, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
May 14, 2026 | May 14, 2026 |
All 402 Gri Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.